Jilin Province Huinan Changlong Bio-pharmacy Company Limited (HKG:8049)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.420
-0.020 (-0.82%)
Apr 24, 2026, 3:51 PM HKT
Market Cap1.36B +39.1%
Revenue (ttm)1.00B +2.4%
Net Income221.32M +7.9%
EPS0.40 +7.9%
Shares Out560.25M
PE Ratio6.13
Forward PEn/a
Dividend0.27 (11.19%)
Ex-Dividend DateJun 24, 2025
Volume8,000
Average Volume109,600
Open2.420
Previous Close2.440
Day's Range2.420 - 2.420
52-Week Range1.600 - 2.550
Beta0.24
RSI64.09
Earnings DateMar 31, 2026

About HKG:8049

Jilin Province Huinan Changlong Bio-pharmacy Company Limited manufactures and distributes Chinese medicines and pharmaceutical products in the People’s Republic of China. The company provides Edaravone injection, compound brain comfort capsules, haikun kidney capsules, cefpirome sulfate for injections, Cefpiramide for injections, anti-bone hyperplasia tablets, Lysine zinc gluconate tablets, and Qianlie Guihuang Tablets. It markets its products under the Changlong and Qing Tong brands. The company also engages in the manufacture and distribution... [Read more]

Sector Healthcare
Founded 1989
Employees 1,107
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 8049
Full Company Profile

Financial Performance

In 2025, HKG:8049's revenue was 901.87 million, an increase of 2.35% compared to the previous year's 881.16 million. Earnings were 198.88 million, an increase of 7.94%.

Financial numbers in CNY Financial Statements